Staccato alprazolam study for prolonged seizures in teens and adults
Part of Brain & nervous system clinical trials.
This Phase 3 trial tests whether staccato alprazolam can reduce and manage “prolonged seizures” that happen repeatedly in people with epilepsy. It also checks safety—especially breathing and heart-related side effects—while participants continue their usual seizure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) must be at least 12 years old at the start of the study.
- You need a study caregiver age 18+ who can watch and recognize your seizure episodes every day.
- You must have epilepsy (focal, generalized, or both) and past “stereotypical” prolonged seizures that match the required timing pattern (focal or generalized, with minimum durations).
- In the last 6 months, you must have had at least 4 similar prolonged seizure episodes, and the last 2 must be within the last 3 months.
- Your antiseizure medicine plan must be stable for about 30 days before screening (no adding/removing seizure medicines; benzodiazepine changes are restricted).
- A recent brain scan (CT or MRI) must show no progressive brain/nerve disease, and you must meet key heart/lung screening checks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests the safety and side effects of Staccato alprazolam for teens and adults (12+) who have certain types of long-lasting seizures. It may help people by offering a specific medicine option aimed at stopping prolonged seizure episodes under close medical study.
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Hear when a new Stereotypical Prolonged Seizures trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.